TGA warns on ketoacidosis
SERIOUS cases of diabetic ketoacidosis have been reported in association with sodium glucose co-transporter 2 (SGLT2) inhibitors, the TGA warns.
Australian sponsors of drugs in this class are alerting doctors to warn patients about the signs and symptoms of metabolic acidosis such as dyspnoea, nausea, vomiting, excessive thirst, abdominal pain and drowsiness or confusion.
The affected agents are empagliflozin (Jardiance, Boehringer Ingelheim), dapagliflozin (Forxiga and Xigduo XR, AstraZeneca) and canagliflozin (Invokana, Janssen-Cilag),
Treatment with SGLT2